Gigamon Inc. v. Apcon, Inc.

CourtDistrict Court, E.D. Texas
DecidedMarch 29, 2022
Docket2:19-cv-00300
StatusUnknown

This text of Gigamon Inc. v. Apcon, Inc. (Gigamon Inc. v. Apcon, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gigamon Inc. v. Apcon, Inc., (E.D. Tex. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION

GIGAMON INC., § §

§ Plaintiff, §

§ v. § CIVIL ACTION NO. 2:19-CV-00300-JRG

§ APCON, INC., § § Defendant. §

MEMORANDUM OPINION AND ORDER Before the Court is Defendant Apcon, Inc.’s (“Apcon”) Motion for Attorneys’ Fees Pursuant to 35 U.S.C. § 285 (the “Motion”) (Dkt. No. 321). Having considered the Motion and the subsequent briefing, and for the reasons set forth herein, the Motion is DENIED. I. BACKGROUND Plaintiff Gigamon Inc. (“Plaintiff” or “Gigamon”) filed suit against Defendant Apcon, Inc. (“Defendant” or “Apcon”), alleging that Apcon’s Series 3000 and Series 4000 products (the “Accused Products”) infringe U.S. Patent Nos. 8,570,862 (“the ’862 Patent”); 8,824,466 (“the ’466 Patent”); 8,873,557 (“the ’557 Patent”); 9,077,656 (“the ’656 Patent”); and 9,769,049 (“the ’049 Patent”) (collectively, the “Asserted Patents”). (Dkt. No. 1). A jury trial was held beginning on April 16, 2021. (Dkt. No. 286). Gigamon asserted six claims across the five Asserted Patents: claims 1 and 8 of the ’862 Patent; claim 12 of the ’466 Patent; claim 10 of the ’557 Patent; claim 14 of the ’656 Patent); and claim 16 of the ’049 Patent (collectively, the “Asserted Claims”). (Dkt. No. 296). The jury returned a verdict of no infringement and invalidity with respect to all Asserted Claims (see id.), and the Court subsequently entered Final Judgment. (Dkt. No. 306). II. LEGAL STANDARD In “exceptional cases,” a district court “may award reasonable attorney fees to the prevailing party” pursuant to 35 U.S.C. § 285. An “exceptional case” is “simply one that stands out from others with respect to the substantive strength of a party’s litigating position . . . or the unreasonable manner in which the case was litigated.” Octane Fitness, LLC v. ICON Health & Fitness, Inc., 134 S. Ct. 1749, 1756 (2014); see also Highmark Inc. v. Allcare Health Mgmt. Sys.,

Inc., 134 S. Ct. 1744, 1748 (2014) (noting that “the word ‘exceptional’ in § 285 should be interpreted in accordance with its ordinary meaning” (citing Octane Fitness, 134 S. Ct. at 1755)). Notably, it is not necessary that the litigation conduct at issue be independently sanctionable, e.g., because it involves bad faith or some other misconduct. See id. at 1756–57 (holding that “a district court may award fees in the rare case in which a party’s unreasonable conduct—while not necessarily independently sanctionable—is nonetheless so ‘exceptional’ as to justify an award of fees”). The Supreme Court has been clear that district courts must determine whether any particular case is “exceptional” in a “case-by-case exercise of their discretion, considering the totality of the circumstances.” Octane Fitness, 134 S. Ct. at 1756. Whether a case is “exceptional”

or not “is a factual determination,” Forcillo v. Lemond Fitness, Inc., 168 F. App’x 429, 430 (Fed. Cir. 2006), and the court must make its discretionary determination by a “preponderance of the evidence.” Octane Fitness, 134 S. Ct. at 1758 (rejecting the prior requirement that a patent litigant establish its entitlement to fees under § 285 by “clear and convincing” evidence). A district court’s determination of whether a case is “exceptional” under § 285 is reviewed for an abuse of discretion. See Highmark Inc., 134 S. Ct. at 1748; see also Checkpoint Sys., Inc. v. All-Tag Sec. S.A., 858 F.3d 1371, 1374 (Fed. Cir. 2017) (“On appeal, all aspects of a district court’s § 285 determination are reviewed for an abuse of discretion.” (citation omitted)). In assessing the “totality of the circumstances,” courts may consider factors such as “frivolousness, motivation, objective unreasonableness (both in the factual and legal components of the case) and the need in particular circumstances to advance considerations of compensation and deterrence.” Octane Fitness, 134 S. Ct. at 1756 n.6 (citing Fogerty v. Fantasy, Inc., 510 U.S.

517, 534 n.9 (1994) (addressing a similar fee-shifting provision in the Copyright Act)). Although a party’s conduct need not be independently sanctionable to warrant an award of fees under § 285, (id. at 1756–57), fee awards should not be used “as a penalty for failure to win a patent infringement suit.” See id. at 1753 (quotation omitted); see also Checkpoint Sys., Inc., 858 F.3d at 1376. Although an exceptional case finding is no longer constrained to “inequitable conduct before the PTO; litigation misconduct; vexatious, unjustified, and otherwise bad faith litigation; a frivolous suit or willful infringement,” Epcon Gas Sys., Inc. v. Bauer Compressors, Inc., 279 F.3d 1022, 1034 (Fed. Cir. 2002), “the absence of such conduct also weighs against an award” of fees under § 285. AstraZeneca AB v. Aurobindo Pharma Ltd., 232 F. Supp. 3d 636, 649 (D. Del. 2017).

III. DISCUSSION Apcon moves for fees on two grounds. First, Apcon argues that Gigamon continued to assert an infringement theory that the Court rejected during claim construction. (Dkt. No. 321 at 7). Second, Apcon contends that Gigamon litigated this case in an unreasonable manner by 1) asserting a large number of claims throughout discovery; 2) bringing an untimely motion for curative instructions during trial; and 3) bringing this lawsuit to disrupt Apcon’s business and curtail its efforts to sell the company. (Id. at 12–17). The Court addresses each argument in turn. A. Claim Construction Apcon argues that Gigamon’s infringement theory was objectively unreasonable at least after the Court issued its Markman Order. (Dkt. No. 321 at 7). During claim construction with respect to the ’862, ’466, ’656, and ’049 Patents (the “Port Patents”), the Court construed “network port” to mean “a port configured to be connected to a network (and not configured to be connected to an instrument),” while “instrument port” was construed to mean “a port configured to be connected to an instrument (and not configured to be connected to a network).” (Dkt. No. 114 at

23). Gigamon offered that no construction was necessary, and alternatively proposed “a port capable of being connected to” a network or instrument. In its analysis, the Court stated that “a single port cannot be both a ‘network port’ and an ‘instrument port’ at the same time.” (Id. at 20). Thus, the Court found, “a port configured to be connected to a network is not at the same time configured to be connected to an instrument, and a port configured to be connected to an instrument is not at the same time configured to be connected to a network.” (Id.). The Court rejected Gigamon’s “capability” construction as “overbroad,” finding the claims “requir[e] actual configuration, not mere capability.” (Id. at 23). The Court also rejected Apcon’s position that a “network port” or “instrument port” must be “specifically designated.” (Id. at 21). Apcon argues that before the Markman Order was issued, Gigamon “accused every port

on Apcon’s devices of being both a ‘network port’ and an ‘instrument port’ at the same time.” (Dkt. No. 321 at 9).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fogerty v. Fantasy, Inc.
510 U.S. 517 (Supreme Court, 1994)
Forcillo v. Lemond Fitness, Inc.
168 F. App'x 429 (Federal Circuit, 2006)
Octane Fitness, LLC v. ICON Health & Fitness, Inc.
134 S. Ct. 1749 (Supreme Court, 2014)
Highmark Inc. v. Allcare Health Management System, Inc.
134 S. Ct. 1744 (Supreme Court, 2014)
Checkpoint Systems, Inc. v. All-Tag Security S.A.
858 F.3d 1371 (Federal Circuit, 2017)
AstraZeneca AB v. Aurobindo Pharma Ltd.
232 F. Supp. 3d 636 (D. Delaware, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Gigamon Inc. v. Apcon, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/gigamon-inc-v-apcon-inc-txed-2022.